Multi-epitope mRNA vaccine targeting esophageal squamous cell carcinoma shows antitumor responses in preclinical studies
Background: A vaccine targeting shared tumor antigens
The multi-epitope mRNA vaccine IPM514, designed to target esophageal squamous cell carcinoma (ESCC), elicited antigen-specific T-cell responses and antitumor activity in in vitro experiments using human samples and in mouse models. In mice, combining it with PD-1 blockade enhanced immune responses compared with monotherapy. However, this was not a clinical trial in which patients received the vaccine to assess therapeutic efficacy.
Treatment options are limited for ESCC that has become resistant to immune checkpoint inhibitors (ICIs). The researchers targeted tumor-associated antigens commonly expressed in tumors from multiple patients. This approach combines shared antigens, unlike personalized vaccines, which select antigens by analyzing each patient’s mutations. Here, “broadly applicable” means designed for use across multiple patients; it does not mean effective in every patient.
Key findings: Separately evaluating antigen composition and conditions for applicability
The researchers analyzed data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx), then filtered candidate antigens using normal-tissue expression data. They selected 15 fragments from nine antigens, focusing on epitopes—antigen regions recognized by T cells—that can be presented by the human leukocyte antigen (HLA) molecules HLA-A02:01 and HLA-A11:01. The mRNA encoding these fragments was packaged in lipid nanoparticles (LNPs) to create IPM514.
Tumors from all 132 patients with ESCC at Beijing Cancer Hospital expressed at least one target antigen, and more than 90% expressed at least three. About 51% of patients carried one of the two HLA types used in the vaccine design. Fifty-eight patients—44% of the cohort—met both conditions: a matching HLA type and expression of at least three target antigens. These figures describe molecular conditions in this cohort; they are not clinical response rates or estimates of applicability to the global population.
In experiments using samples from healthy donors, dendritic cells treated with mRNA or mRNA-LNPs were cultured with T cells, and expansion of antigen-specific CD8⁺ T cells was confirmed. Among these, T cells expanded using mRNA-treated dendritic cells killed ESCC cells engineered to have matching HLA types, as well as some tongue and lung squamous cell carcinoma cells, in cell-line experiments. The extent of killing varied by cell line. Separately, when peripheral blood mononuclear cells (PBMCs) from 22 patients were stimulated with a mixture of vaccine-derived peptides, antigen-specific T-cell expansion was observed in 15 patients (68%). This experiment using patient samples evaluated in vitro peptide responses; it did not measure responses to vaccination.
In vivo efficacy was assessed in a model implanted with MC38 cells derived from mouse colon cancer and engineered to express human HLA and vaccine antigens. In the HLA-A2.1 model, median survival increased significantly from 34 days in controls to 52 days in the 10 μg vaccine group. However, tumor-volume differences at individual time points were not statistically significant in this model. Separate prophylactic vaccination and tumor-rechallenge experiments also reported protective effects.
Implications and outlook: Combination potential and immune escape
The PD-1 blockade combination group showed increased antigen-specific T-cell responses and T-cell infiltration into tumors compared with monotherapy. Single-cell analyses showed stronger cell-to-cell interactions related to antigen presentation and a shift in macrophages and monocytes toward antitumor phenotypes.
However, antigen and HLA expression in tumor cells decreased. The researchers interpreted this as a consequence of selection pressure from antigen-specific killing, while noting that antigen loss or HLA downregulation could lead to immune escape. Increased interactions related to antigen presentation should not be interpreted as increased HLA expression in all tumor cells.
Treatment began four days after tumor implantation, at an early stage, and the engineered mouse tumors do not fully reproduce the diversity of human ESCC. Therapeutic efficacy has not been demonstrated in patients with ICI-resistant disease. Safety and efficacy in humans, markers for predicting response, and the sequence of vaccination and combination treatment need to be assessed in subsequent clinical trials. The study’s results and conditions are reported in the NPJ Vaccines paper.
EMOTION_TAG: interesting
Esophageal squamous cell carcinoma (ESCC) has limited treatment options post-immune checkpoint inhibitor (ICI) resistance. We developed IPM514, a universal multi-epitope mRNA lipid nanoparticle (LNP) vaccine targeting tumor-associated antigens identified via transcriptomic analysis of TCGA/GTEx datasets and validated in 132 ESCC patients. IPM514 contains 15 fragments from 9 antigens, covering most patients and over half of HLA subtypes. Peripheral blood mononuclear cells (PBMCs) from healthy donors and ESCC patients stimulated with IPM514 effectively expanded specific T cells that exhibited significant cytotoxic activity against ESCC and other squamous cell carcinomas with similar antigen profiles. In HLA-transgenic mouse models, IPM514 suppressed tumor growth, extended survival, and provided durable protection. Importantly, combination therapy with PD-1 blockade augmented antitumor efficacy by promoting immune cell infiltration, upregulating antigen presentation pathways, and reprogramming the tumor microenvironment toward an anti-tumorigenic state. These results demonstrate IPM514 represents a promising novel mRNA vaccine strategy for improving ESCC immunotherapy.
IPM514 provides preclinical evidence to support evaluating an mRNA vaccine combining shared tumor antigens together with PD-1 blockade. In subsequent clinical trials, investigators could select participants based on their HLA types and tumor antigen expression, then assess whether vaccine-induced T-cell responses translate into actual tumor control. However, the antigen and HLA matching rates in this cohort alone cannot predict treatment response.
Considering that treatment began at an early tumor stage in the model, the researchers suggested that an adjuvant setting targeting minimal residual disease might be more suitable than treating large tumors. This is a hypothesis to test, not a clinical recommendation. Alongside safety and efficacy, clinical development will need to monitor immune escape associated with antigen loss and reduced HLA expression.